Alnylam’s product sales jump 52% as it enlarges a pivotal heart-disease trial
Alnylam ($ALNY) reported third-quarter 2026 product revenue of $1.29 billion, up 52%, led by Amvuttra and Onpattro’s combined $1.15 billion contribution. Total revenue increased a slower 17% to $1.46 billion because collaboration revenue declined against a prior-year milestone payment. GAAP operating income fell 6% to $345.8 million, showing that faster product sales did not translate directly into higher operating profit. The company maintained its 2026 financial guidance. Alnylam also increase
0